曲美他嗪片治疗冠心病心力衰竭的临床研究

发布时间：2018-01-30 07:16

本文关键词： 曲美他嗪片冠心病心力衰竭安全性　出处：《中国临床药理学杂志》2017年15期 　论文类型：期刊论文

【摘要】：目的观察曲美他嗪片治疗冠心病心力衰竭的临床疗效及安全性。方法将123例冠心病心力衰竭患者随机分为对照组61例和试验组62例。对照组予以阿司匹林100 mg,qd,口服+阿托伐他汀钙20 mg,qn,口服+培哚普利4 mg,qd,口服+琥珀酸美托洛尔缓释片47.5 mg,qd,口服;试验组在对照组治疗的基础上,予以曲美他嗪每次20 mg,tid,口服。2组患者均治疗6个月。比较2组患者的临床疗效、左心室射血分数(LVEF)、6 min步行试验和脑钠肽(BNP),以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分为80.65%(50/62例)和72.13%(44/61例),差异无统计学意义(P0.05)。治疗后,试验组和对照组的LVEF分别为(38.85±4.72)%和(36.53±3.10)%,6 min步行距离分别为(375.23±43.84)和(344.64±38.92)m,血浆BNP分别为(335.48±211.36)和(420.52±237.47)pg·m L~(-1),差异均有统计学意义(均P0.05)。试验组的药物不良反应主要有恶心、呕吐、皮肤瘙痒,对照组的药物不良反应主要有恶心、胃部不适。试验组和对照组的药物不良反应发生率分别为6.45%和3.27%,差异无统计学意义(P0.05)。结论曲美他嗪片虽不能明显提高冠心病心力衰竭患者的临床疗效,但其能显著地改善患者的心功能和运动耐量,降低BNP水平,且不增加药物不良反应的发生率。
[Abstract]:Objective to observe the clinical efficacy and safety of trimetazidine tablets in the treatment of coronary heart failure. Methods 123 patients with coronary heart failure were randomly divided into control group (61 cases) and trial group (62 cases). Lin 100. Mg. QD, oral administration of Atto vastatin calcium 20 mg / g QN, perindopril 4 mg / QD, oral metoprolol succinate 47.5 mg / kg QD, oral administration of metoprolol succinate 47.5 mg / kg QD; The experimental group was treated with trimetazidine 20 mg / time for 6 months on the basis of the control group. The clinical efficacy of the two groups was compared. Left ventricular ejection fraction (LVEF) 6 min walking test, brain natriuretic peptide (BNPP), and adverse drug reactions. The total effective rates of the test group and the control group were 80.65% 50 / 62 cases and 72.13% 44 / 61 cases respectively. The difference was not statistically significant (P 0.05). The LVEF of test group and control group were 38.85 卤4.72% and 36.53 卤3.10% respectively. The walking distance of 6 min was 375.23 卤43.84) and 344.64 卤38.92 m respectively. The plasma BNP levels were 335.48 卤211.36) and 420.52 卤237.47 PG 路mL ~ (-1), respectively. The differences were statistically significant (P0.05). The adverse drug reactions in the trial group were mainly nausea, vomiting, skin itching, and in the control group, the main adverse drug reactions were nausea. The incidence of adverse drug reactions in the trial group and the control group was 6.45% and 3.27% respectively. Conclusion trimetazidine tablets can not significantly improve the clinical efficacy of patients with coronary heart failure, but it can significantly improve the cardiac function and exercise tolerance of patients with coronary heart disease. The level of BNP was reduced and the incidence of adverse drug reactions was not increased.
【作者单位】：厦门大学附属中山医院心内科;
【分类号】：R541.4;R541.6
【正文快照】： (厦门大学附属中山医院心内科,福建厦门361000)GUO Feng,ZHOU Nai-zhen(Department of Cardiovascular,AffiliatedZhongshan Hospital,Xiamen University,Xiamen 361000,Fujian Province,China)心力衰竭(HF)是由于各种心脏结构或功能性病变,引起心脏舒缩功能障碍,心排血量降低

【参考文献】